Cohen J A, Carter J L, Kinkel R P, Schwid S R
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA.
J Neuroimmunol. 1999 Jul 1;98(1):29-36. doi: 10.1016/s0165-5728(99)00078-8.
There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary.
在不可逆的组织损伤和由此导致的永久性残疾出现之前，尽早开始针对复发型多发性硬化症（R-MS）的疾病修正治疗的动力越来越大。然而，目前所有获批用于复发型多发性硬化症的治疗方法，对于患者群体而言都只是部分有效。治疗失败可能是由于不遵守治疗方案、出现无法耐受的不良反应、产生中和抗体或疾病无反应。为R-MS患者进行疾病修正治疗的神经科医生必须对这些问题保持警惕，并在必要时采取适当行动。
